Shares of biopharmaceutical company Veru Inc. (NASDAQ:VERU) have tanked today after the meeting of the U.S. Food and Drug Administration’s (FDA) advisory committee for the review of Veru’s marketing application for sabizabulin was postponed.
Sabizabulin is an oral therapy for the treatment of COVID-19. The regulatory agency has now pushed the meeting to November 9 from the earlier date of October 6.
Read full Disclosure
